Real-world Analysis of Clinical Characteristics and Treatment Patterns in Patients with Type 2 Diabetes in the United Arab Emirates

Fatheya Al-Awadi; Abdul Jabbar; Tarek Fiad; Khadija Hafidh; Mohamed Hassanein; Fatih Tangi; Soniya Rai; Kathryn Tebbs; Lewis Harrison; Tatjana Isailovic

doi:10.18502/ddej.v31i1.19920

Authors

Fatheya Al-Awadi Dubai Hospital, Dubai
Abdul Jabbar Medcare Hospital, Dubai https://orcid.org/0000-0002-8851-7615
Tarek Fiad Sheikh Khalifa Medical City, Abu Dhabi
Khadija Hafidh Dubai Hospital, Dubai https://orcid.org/0000-0002-3632-4336
Mohamed Hassanein Dubai Hospital, Dubai
Fatih Tangi Eli Lilly UAE (Suisse), Dubai
Soniya Rai Eli Lilly UAE (Suisse), Dubai
Kathryn Tebbs Adelphi Real World, Bollington https://orcid.org/0000-0001-8633-3153
Lewis Harrison Adelphi Real World, Bollington
Tatjana Isailovic Eli Lilly UAE (Suisse), Dubai

DOI:

https://doi.org/10.18502/ddej.v31i1.19920

Keywords:

United Arab Emirates, type 2 diabetes, observational study, clinical characteristics, treatment

Abstract

Introduction: This real-world study examined the demographics, clinical characteristics, and treatment of patients with type 2 diabetes mellitus (T2DM) in routine clinical practice in the UAE.

Methods: Data were drawn from the Adelphi Real World Diabetes Disease Specific Programme (DSP)^TM, a cross-sectional survey of physicians and their patients with T2DM in the UAE from July to October 2022. Patient data were divided into four stratification factors: physician care, HbA1c level, obesity status, and age, with factors then divided into subgroups.

Results: Seventy physicians provided data for 849 patients (mean [SD] age 46.4 [10.6] years, with 31.1% of patients ≤40 years of age; 56.8% male; BMI 28.5 [4.4] kg/m², with 27.3% of patients having a BMI ≥30 kg/m²). The mean HbA1c was 9.0% [1.1%] at diagnosis, 8.8% [1.1%] at the start of current treatment, and 7.5% [0.9%] at the last follow-up visit. Younger age, lower BMI, and shorter time since diagnosis were associated with a lower most recent HbA1c result (each p<0.0001). Overall, 84.5% of patients did not achieve the HbA1c target set by the physician post-treatment. The mean number of treatments was 1.3, and most patients (73%) only received one line of treatment. It took 3.3 years to switch patients from their previous to current therapy; only 59.7% of patients switched because of inadequate HbA1c reduction.

Conclusion: Despite receiving prescribed antidiabetic treatment, a high proportion of patients in our survey did not reach their target HbA1c. High HbA1c was correlated with age, time since diagnosis, and BMI, indicating a need for more efficacious treatment, particularly for older and high-BMI patients. Use of more optimal treatments may improve glycemic control and outcomes in this patient population.

References

[1] International Diabetes Federation. IDF Diabetes Atlas. 10th ed2021.

[2] Sulaiman N, Albadawi S, Abusnana S, Mairghani M, Hussein A, Al Awadi F, et al. High prevalence of diabetes among migrants in the United Arab Emirates using a cross-sectional survey. Scientific reports. 2018;8(1):6862.

[3] Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European heart journal. 2020;41(2):255-323.

[4] Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. The lancet Diabetes & endocrinology. 2016;4(7):588-97.

[5] Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular diabetology. 2018;17:1-19.

[6] Shen Y, Cai R, Sun J, Dong X, Huang R, Tian S, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017;55:66-76.

[7] Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes, Obesity and Metabolism. 2022;24(3):365-76.

[8] ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S97-s110.

[9] Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2022;45(11):2753- 86.

[10] Control D, Group CTR. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England journal of medicine. 1993;329(14):977-86.

[11] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. New England journal of medicine. 2008;359(15):1577-89.

[12] Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes care. 2019;42(3):416-26.

[13] Diabetes Trials Unit University of Oxford. 44-year UKPDS Legacy Effects. EASD; 21 Sept 2022.

[14] Alawadi F, Abusnana S, Afandi B, Aldahmani KM, Alhajeri O, Aljaberi K, et al. Emirates Diabetes Society consensus guidelines for the management of type 2 diabetes mellitus–2020. Dubai Diabetes and Endocrinology Journal. 2020;26(1):1-20.

[15] ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes care. 2023;46(Supplement_1):S140-S57.

[16] Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Primary care diabetes. 2017;11(1):3-12.

[17] Andreozzi F, Candido R, Corrao S, Fornengo R, Giancaterini A, Ponzani P, et al. Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review. Diabetology & metabolic syndrome. 2020;12:1-11.

[18] Hajat C, Harrison O, Al Siksek Z. Weqaya: a population-wide cardiovascular screening program in Abu Dhabi, United Arab Emirates. American journal of public health. 2012;102(5):909-14.

[19] Jelinek HF, Osman WM, Khandoker AH, Khalaf K, Lee S, Almahmeed W, et al. Clinical profiles, comorbidities and complications of type 2 diabetes mellitus in patients from United Arab Emirates. BMJ Open Diabetes Research and Care. 2017;5(1):e000427.

[20] Alzaabi A, Al-Kaabi J, Al-Maskari F, Farhood AF, Ahmed LA. Prevalence of diabetes and cardiometabolic risk factors in young men in the United Arab Emirates: A cross-sectional national survey. Endocrinology, diabetes & metabolism. 2019;2(4):e00081.

[21] Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes–a means to understand. Current medical research and opinion. 2008;24(11):3063-72.

[22] Babineaux S, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ open. 2016;6(8):e010352.

[23] Boye KS, Lage MJ, Shinde S, Thieu V, Bae JP. Trends in HbA1c and body mass index among individuals with type 2 diabetes: evidence from a US database 2012–2019. Diabetes Therapy. 2021;12(7):2077-87.

[24] Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004. Diabetes care. 2008;31(10):1991-6.

[25] Yki-Järvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism. 1997;82(12):4037-43.

[26] Boye KS, Stein D, Matza LS, Jordan J, Yu R, Norrbacka K, et al. Timing of GLP-1 receptor agonist initiation for treatment of type 2 diabetes in the UK. Drugs in R&D. 2019;19:213-25.

[27] Leung E, Wongrakpanich S, Munshi MN. Diabetes management in the elderly. Diabetes spectrum: a publication of the American Diabetes Association. 2018;31(3):245.

[28] Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in US adults, 1999–2018. New England Journal of Medicine. 2021;384(23):2219-28.

[29] de Pablos-Velasco P, Parhofer KG, Bradley C, Eschwège E, Gönder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clinical endocrinology. 2014;80(1):47-56.

[30] Lau KT, Wong CK, Au IC, Lau WC, Man KK, Chui CS, et al. Switching to Versus Addition of Incretin- Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors. Journal of the American Heart Association. 2022;11(7):e023489.

[31] Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: a long-term cost-effectiveness analysis. Diabetes, Obesity and Metabolism. 2018;20(8):1921-7.

[32] Schmittdiel JA, Uratsu CS, Karter AJ, Heisler M, Subramanian U, Mangione CM, et al. Why don’t diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. Journal of general internal medicine. 2008;23:588-94.

[33] Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Therapeutic advances in endocrinology and metabolism. 2021;12:2042018820980225.

[34] Okemah J, Peng J, Qui nones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Advances in therapy. 2018;35(11):1735-45.

[35] Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine. 2006;355(23):2427- 43.

[36] DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, et al. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Ann Intern Med. 2022;175(9):1298-304.

[37] European Pharmaceutical Market Research Association (EPhMRA). Code of Conduct 2022 [Available from: https://www.ephmra.org/sites/default/files/2022-08/EPHMRA%202022%20Code%20of% 20Conduct.pdf].